English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/221206
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

AuthorsSoria-Juan, Bárbara; Escacena, Natalia ; Capilla-González, Vivian; Aguilera, Yolanda ; Llanos, Lucía; Tejedo Huamán, Juan Rigoberto ; Bedoya Bergua, Francisco Javier ; Juan, Verónica; Cuesta, Antonio de la; Ruiz-Salmerón, Rafael; Andreu, Enrique; Grochowicz, Lukas; Prósper, Felipe; Sánchez-Guijo, Fermín; Lozano, Francisco S.; Miralles, Manuel; Río-Solá, Lourdes del; Castellanos, Gregorio; Moraleda, José M.; Sackstein, Robert; García-Arranz, Mariano; García-Olmo, Damián; Martín, Franz ; Hmadcha, Abdelkrim ; Soria Escoms, Bernat
Issue Date2019
PublisherFrontiers Media
CitationFrontiers in Immunology 10: 1151 (2019)
AbstractCell therapy is a progressively growing field that is rapidly moving from preclinical model development to clinical application. Outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy to deal with unmet medical treatment needs for several disorders with no therapeutic options. Among adult stem cells, mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety and feasibility of autologous MSC-based therapy has been established; however, their indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies. While MSCs derived from diverse tissues share common properties depending on the type of clinical application, they markedly differ within clinical trials in terms of efficacy, resulting in many unanswered questions regarding the application of MSCs. Additionally, our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that the therapeutic efficacy of these cells in different animal models has only been partially reproduced in humans through clinical trials. Therefore, it is crucial to develop new research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms used by these cells, as well as to be able to offer a next generation of stem cell that can be routinely used in a cost-effective and safe manner in stem cell-based therapies targeting CLI.
DescriptionThe Collaborative Working Group “Noma Project Team”.
Publisher version (URL)https://doi.org/10.3389/fimmu.2019.01151
URIhttp://hdl.handle.net/10261/221206
DOIhttp://dx.doi.org/10.3389/fimmu.2019.01151
E-ISSN1664-3224
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
costmellitu.pdf1,52 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.